Versant Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Versant Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$524K	Sell	1,055 -11	-1%	-$4.88K	0.05%	275
2026 Q1	$476K	Buy	1,066 +370	+53%	+$173K	0.05%	271
2025 Q4	$316K	Buy	696 +478	+219%	+$206K	0.04%	345
2025 Q3	$85.4K	Sell	218 -456	-68%	-$191K	0.01%	784
2025 Q2	$300K	Buy	674 +47	+7%	+$21.7K	0.05%	319
2025 Q1	$304K	Buy	627 +297	+90%	+$138K	0.05%	287
2024 Q4	$133K	Buy	330 +169	+105%	+$78.3K	0.03%	248
2024 Q3	$74.9K	Buy	161 +29	+22%	+$13.9K	0.02%	322
2024 Q2	$61.9K	Buy	132 +98	+288%	+$42.5K	0.02%	320
2024 Q1	$14.2K	Hold	34	–	–	﹤0.01%	619
2023 Q4	$13.8K	Hold	34	–	–	﹤0.01%	620
2023 Q3	$11.8K	Hold	34	–	–	﹤0.01%	675
2023 Q2	$12K	Buy	34 +10	+42%	+$3.37K	﹤0.01%	708
2023 Q1	$7.56K	Hold	24	–	–	﹤0.01%	806
2022 Q4	$6.93K	Hold	24	–	–	﹤0.01%	779
2022 Q3	$7K	Hold	24	–	–	﹤0.01%	765
2022 Q2	$7K	Hold	24	–	–	﹤0.01%	774
2022 Q1	$6K	Hold	24	–	–	﹤0.01%	848
2021 Q4	$5K	Sell	24 -7	-23%	-$1.36K	﹤0.01%	922
2021 Q3	$6K	Sell	31 -51	-62%	-$9.96K	﹤0.01%	852
2021 Q2	$17K	Buy	82 +13	+19%	+$2.72K	0.01%	541
2021 Q1	$15K	Buy	69 +43	+165%	+$9.45K	0.01%	658
2020 Q4	$6K	Hold	26	–	–	﹤0.01%	885
2020 Q3	$7K	Hold	26	–	–	﹤0.01%	779
2020 Q2	$7K	Hold	26	–	–	﹤0.01%	760
2020 Q1	$6K	Buy	26 +3	+13%	+$688	﹤0.01%	723
2019 Q4	$5K	Hold	23	–	–	﹤0.01%	953
2019 Q3	$3K	Sell	23 -12	-34%	-$2.12K	﹤0.01%	1116
2019 Q2	$6K	Sell	35 -26	-43%	-$4.54K	﹤0.01%	925
2019 Q1	$11K	Hold	61	–	–	﹤0.01%	876
2018 Q4	$10K	Hold	61	–	–	﹤0.01%	833
2018 Q3	$11K	Hold	61	–	–	﹤0.01%	881
2018 Q2	$10K	Hold	61	–	–	﹤0.01%	897
2018 Q1	$9K	Hold	61	–	–	﹤0.01%	923
2017 Q4	$9K	Hold	61	–	–	﹤0.01%	949
2017 Q3	$9K	Hold	61	–	–	﹤0.01%	901
2017 Q2	$7K	Hold	61	–	–	﹤0.01%	976
2017 Q1	$6K	Hold	61	–	–	﹤0.01%	1007
2016 Q4	$4K	Sell	61 -52	-46%	-$4.23K	﹤0.01%	1087
2016 Q3	$9K	Buy	113 +15	+15%	+$1.42K	0.01%	856
2016 Q2	$8K	Hold	98	–	–	﹤0.01%	863
2016 Q1	$7K	Hold	98	–	–	﹤0.01%	881
2015 Q4	$12K	Buy	+98	New	+$11.8K	0.01%	686

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Versant Capital Management's VRTX Position: Q2 2026 in Review

Versant Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1% in Q2 2026, selling an estimated $4.88K and leaving 1,055 shares worth $524K. The position accounts for 0.05% of the portfolio, ranked #275.

Versant Capital Management first reported a position in VRTX in Q4 2015 and has held it in 43 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Versant Capital Management held 1,055 shares of Vertex Pharmaceuticals worth $524K as of Q2 2026.
Versant Capital Management sold 11 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.88K.
Vertex Pharmaceuticals made up 0.05% of Versant Capital Management's portfolio in Q2 2026, its #275 holding.
Versant Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.